MAPT and Alzheimer disease: Our findings might be explained by differences in the PET analysis and the low number of AD patients (n = 9) that underwent 18F-Flortaucipir-PET in our cohort, as most scans were from CN and MCI subjects, where tau accumulation and hypometabolism may still be at relatively early or spatially divergent stages.